Loading...
XCSEBAVA
Market cap2.12bUSD
Dec 20, Last price  
192.90DKK
1D
0.47%
1Q
-20.22%
Jan 2017
-22.53%
Name

Bavarian Nordic A/S

Chart & Performance

D1W1MN
XCSE:BAVA chart
P/E
10.28
P/S
2.15
EPS
18.76
Div Yield, %
0.00%
Shrs. gr., 5y
13.47%
Rev. gr., 5y
69.76%
Revenues
7.06b
+124.14%
164,782,000247,596,000175,292,000332,103,000208,805,00074,783,000314,072,000523,601,0001,016,636,0001,212,501,0001,216,815,0001,020,561,0001,006,742,0001,370,151,000500,617,000662,488,0001,852,383,0001,897,875,0003,150,793,0007,062,340,000
Net income
1.48b
P
-53,014,000-94,730,000-160,937,000-63,504,000-216,242,000-395,988,000-576,969,000-324,339,000-240,001,000-46,729,00025,940,00059,426,00030,600,000181,343,000-361,927,000-346,777,000277,521,000-464,775,000-347,382,0001,475,189,000
CFO
1.12b
+408.61%
-76,627,000-58,210,000-194,493,000163,165,00022,411,000-484,139,000-239,862,000-375,236,00020,100,000147,084,000338,749,000105,323,000267,601,000216,065,000-288,529,000-275,910,000571,911,000-358,500,000220,053,0001,119,206,000
Earnings
Mar 05, 2025

Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
URL
https://www.bavarian-nordic.com/
IPO date
Nov 02, 1998
Employees
1,354
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
7,062,340
124.14%
3,150,793
66.02%
1,897,875
2.46%
Cost of revenue
5,636,078
3,221,578
2,211,422
Unusual Expense (Income)
NOPBT
1,426,262
(70,785)
(313,547)
NOPBT Margin
20.20%
Operating Taxes
7,754
15,771
10,345
Tax Rate
0.54%
NOPAT
1,418,508
(86,556)
(323,892)
Net income
1,475,189
-524.66%
(347,382)
-25.26%
(464,775)
-267.47%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,678,442
28,590
2,955,198
BB yield
-12.33%
-0.19%
-17.42%
Debt
Debt current
46,546
1,130,070
895,639
Long-term debt
227,010
699,583
315,767
Deferred revenue
1
2,324,657
2,569,090
Other long-term liabilities
1,097,588
2,891,077
2,729,601
Net debt
(1,605,110)
(1,020,599)
(2,509,987)
Cash flow
Cash from operating activities
1,119,206
220,053
(358,500)
CAPEX
(977,405)
(1,381,575)
(1,058,451)
Cash from investing activities
(945,564)
(877,405)
(2,876,946)
Cash from financing activities
735,832
635,820
3,536,080
FCF
971,534
(1,373,898)
(753,365)
Balance
Cash
1,867,481
2,845,166
3,716,615
Long term investments
11,185
5,086
4,778
Excess cash
1,525,549
2,692,712
3,626,499
Stockholders' equity
10,341,469
7,151,450
7,375,779
Invested Capital
10,050,068
11,415,789
10,175,709
ROIC
13.22%
ROCE
12.29%
EV
Common stock shares outstanding
76,711
70,419
63,104
Price
177.45
-16.85%
213.40
-20.61%
268.80
43.74%
Market cap
13,612,289
-9.42%
15,027,415
-11.41%
16,962,355
67.83%
EV
12,007,179
14,006,816
14,452,368
EBITDA
1,980,083
328,462
74,763
EV/EBITDA
6.06
42.64
193.31
Interest
105,519
119,689
152,060
Interest/NOPBT
7.40%